Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 16/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.32 |
| ▸ | CASR | P41180 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7259102 | 0.81 | ITGB1 (0.42) | ACACBFFAR1CASRPPARGPPARD | |
| SCHEMBL7105624 | 0.77 | ITGB1 (0.40) | ACACB | |
| SCHEMBL7105616 | 0.77 | ITGB1 (0.40) | ACACB | |
| SCHEMBL7105618 | 0.74 | ACACB (0.35) | ACACBFFAR1 | |
| SCHEMBL7716183 | 0.69 | MAPT (0.37) | — | |
| SCHEMBL7716187 | 0.66 | MAPT (0.35) | — | |
| SCHEMBL7716184 | 0.66 | MAPT (0.35) | — | |
| SCHEMBL7710685 | 0.66 | ALDH1A1 (0.34) | ACACBPPARG | |
| SCHEMBL7101246 | 0.66 | ACE (0.53) | PPARGPPARDPPARA | |
| SCHEMBL7101248 | 0.66 | ACE (0.53) | PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162799-A1 | Carbocyclic oxo, carboxy amines such as 3-(4-(3,5-Dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4 -dioxocyclobut-1-enyl)amino)propanoic acid, used as integrin antagonists; antiinflammatory agents | CELLTECH R&D LIMITED (GB) | 2003-08-28 | — | — | US | disclosed |
| US-6518283-B1 | To modify integrin function in such a way as to beneficially modulate cell adhesion | CELLTECH R&D LIMITED (GB) | 2003-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162799-A1 | Carbocyclic oxo, carboxy amines such as 3-(4-(3,5-Dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4 -dioxocyclobut-1-enyl)amino)propanoic acid, used as integrin antagonists; antiinflammatory agents | ICAM1, VCAM1, CCR1 | ACACB 1447/4885FFAR1 66/4885CASR 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.